ASLN
Aslan Pharma ADR
–
Index: NASDAQ; Sector: ; Industry: ;
Marketcap: 37.08M; Volume: 86.41K; AvgVol 3m: 79.41K; Beta: –;
Cost estimate:
P/E: –; EPS: –; EPS growth quarter/prev quarter: 59.70%;
EPS growth this year: -5.20%; EPS growth past 5 years: ;
EPS ttm: -1.30;
P/S: ; P/B: ; P/Cashflow: 5.20; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -190.20%; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: ; Insider Transactions:;
Institutional Ownership: 9.20%; Institutional Transactions: 1.98%;
Data update: 07/10/2020.